Sono-Tek: 3 Key Takeaways for Long-Term Investors

On its second-quarter fiscal 2027 earnings call, held on Oct. 14, 2026, Sono-Tek (NASDAQ:SOTK) announced that first-half revenue rose 6% to $10.9 million as medical market sales nearly quadrupled. This transition toward higher-value production systems should help expand profit margins and secure multiyear order visibility for shareholders.

Three key takeaways from management explain how this strategic evolution shapes the company's long-term outcome.

1. Medical Device Customers Transition From R&D to High-Volume Production

Medical market revenue surged 289% to $7.1 million during the first half of fiscal 2027. This growth matters because clients are advancing beyond initial process development into commercial manufacturing, where systems command a higher average selling price (ASP), or unit price, and generate attractive gross profit margins.

We are seeing customers increasingly move from process development and qualification toward commercial manufacturing.
-- Christopher L. Coccio, Executive Chairman

2. Systems Integration Capabilities Drive Repeat High-Value Orders

The forward-deployed engineering (FDE) team, a specialized engineering group that integrates ultrasonic coating equipment directly into client assembly lines, delivers faster returns on capital than traditional research and development (R&D). A single alternative energy customer recently ordered 10 production-scale systems valued at $7.2 million across three factory locations.

This continued expansion demonstrates the strength of our business model where successful process development leads to high volume manufacturing opportunities and additional orders as our customers expand their production capabilities.
-- R. Stephen Harshbarger, CEO and President

3. Backlog Surge Extends Revenue Visibility Into Fiscal Year 2028

Large-scale system wins have expanded the company's backlog, which represents non-canceled customer orders awaiting delivery. Combined clean energy and medical diagnostic line commitments now total $10.8 million, providing clear sales visibility because most units ship during fiscal year 2028.

Together with the more than $3.6 million medical diagnostic production line order, announced in August. These programs alone now represent more than $10.79 million of backlog with the majority currently expected to be delivered in fiscal year 28.
-- Christopher L. Coccio, Executive Chairman

Looking Ahead

Order momentum is accelerating in specialized industrial markets, and management is openly confident about multiyear growth prospects. Proprietary system designs and direct customer integration create durable competitive barriers. Management is watching factory floor expansion timing and pricing discipline as production orders scale. However, management also reiterated flat to modest revenue growth for fiscal 2027

The recent record order activity also gives us increased visibility into fiscal 2028 while we continue to pursue additional opportunities across medical, microelectronics, industrial, and alternative energy applications.
-- R. Stephen Harshbarger, CEO and President

With $17.7 million in cash and zero debt, the balance sheet provides ample liquidity to support manufacturing expansion and working capital needs for complex production lines.

Overall, we believe that our balance sheet and backlog position the company very well as we move through the remainder of fiscal 27 and prepare for our next fiscal year.
-- Stephen J. Bagley, Chief Financial Officer

This article was created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. The Motley Fool has positions in and recommends Sono-Tek. The Motley Fool has a disclosure policy.